PharmaPoint: Rheumatoid Arthritis - India Drug Forecast And Market Analysis Event-Driven Update
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in India
- Obtain sales forecast from 2011-2022 in India
Table of Contents
1 Table of Contents 41.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 10
3.1.3 Prognosis 13
3.1.4 Quality of Life 13
3.2 Symptoms 14
4 Disease Management 15
4.1 Treatment Overview 18
4.2 India 22
4.2.1 Diagnosis 22
4.2.2 Clinical Practice 22
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 24
5.3 Product Profiles - Major Brands 26
5.3.1 Enbrel (etanercept) 26
5.3.2 Remicade (infliximab) 32
5.3.3 Orencia (abatacept) 36
5.3.4 Actemra/RoActemra (tocilizumab) 40
5.3.5 Rituxan/MabThera (rituximab) 44
5.3.6 Methotrexate Sodium (numerous generic names) 48
5.3.7 DMARDs 51
6 Opportunity and Unmet Need 52
6.1 Overview 52
6.2 Unmet Needs 53
6.2.1 More rheumatologists in the field and physician knowledge of the disease 53
6.2.2 More cost-effective therapies through oral formulation and biosimilars 53
6.2.3 The development of predictive tests and discovery of biomarkers 54
6.2.4 The discovery of curative therapies 54
6.2.5 Improved drug safety and efficacy profiles 54
6.3 Gap Analysis 55
6.4 Opportunities 56
6.4.1 Predictive tools for diagnosis and treatment 56
6.4.2 Target specificity 56
7 Pipeline Assessment 57
7.1 Overview 57
7.2 Promising Drugs in Clinical Development 58
8 Market Outlook 60
8.1 India 60
8.1.1 Forecast 60
8.1.2 Key Events 62
8.1.3 Drivers and Barriers 63
9 Appendix 65
9.1 Abbreviations 65
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
